{"paper_id":"223344f1-71cb-474d-a0c2-7eb23ad2c1b7","body_text":"Abstract\nObjective\nTo evaluate preoperative serum levels of Ca125 and Tag72–4 tumour markers and investigate if abnormal levels correlate to mortality and disease-free survival.\nMethod\nRetrospective observational study of a cohort of 282 women (mean age 62.3, SD 10.5 years) with primary endometrial cancer included all consecutive cases treated in a tertiary Gynaecological oncology Center. Excluded cases with other cancer or previous cancer treatment, major abdominal pathology or inflammation, endometriosis. Preoperative serum Tag72 and Ca125 levels were determined and evaluated in relation to disease-free survival (DFS) and disease-specific overall survival (DOS).\nResults\nRaised Ca125 correlates to worse overall disease-specific survival (66.1 vs 87.8 months, p = 0.021) and Tag72 correlates to shorter disease-free survival (69.2 vs 67.3 months, p = 0.021) and higher recurrence rate (13.5 vs 6 %, p = 0.021). When both Ca125 and Tag72 are abnormal DFS and DOS are worse. 93.3 % (72.3 months) vs 82.4 %, (61.3 months) p = 0.018 and 96.3 % (74.8 months) vs 88.2 %, (65.9 months) p = 0.021, respectively.\nConclusion\nThis study enhances the value of preoperative tumour markers and their prognostic value. Ca125 and Tag72 appear to be good predictors of poor prognosis in patients with endometrial cancer.\nSimilar content being viewed by others\nReferences\nAmant F, Moerman P, Neven P et al (2005) Endometrial cancer. Lancet 366:491–505\nFerlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917. doi:10.1002/ijc.25516\nSorosky JI (2012) Endometrial cancer. Obstet Gynecol 120(2 Pt 1):383–397\nFerlay J, Shin HR, Bray F (2010) GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. Lyon, France: International Agency for Research on Cancer: IARC Cancer Base No. 10\nSorosky JI (2008) Endometrial cancer. Obstet Gynecol 111(2 Pt 1):436–447\nColombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, Sessa C, ESMO Guidelines Working Group (2011) Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi35–vi39\nCancer Research UK. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/uterus\nCreasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S (2006) Carcinoma of the corpus uteri. FIGO 26th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S105–S143\nNiloff JM, Klug TL, Schaetzl E, Zurawski VR Jr, Knapp RC, Bast RC Jr (1984) Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 148:1057–1058\nDuk JM, Aalders JG, Fleuren GJ, de Bruijn HW (1986) CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 155:1097–1102\nPatsner B, Mann WJ, Cohen H, Loesch M (1988) Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma. Am J Obstet Gynecol 158:399–402\nSoper JT, Berchuck A, Olt GJ, Soisson AP, Clarke-Pearson DL, Bast RC Jr (1990) Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. Am J Obstet Gynecol 163:1204–1209\nSood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M (1997) Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 90:441–447\nCherchi PL, Dessole S, Ruiu GA, Ambrosini G, Farina M, Capobianco G, Ambrosini A (1999) The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma. Eur J Gynaecol Oncol 20(4):315–317\nDotters DJ, Preoperative CA (2000) 125 in endometrial cancer: is it useful? Am J Obstet Gynecol 182:1328–1334\nEbina Y, Sakuragi N, Hareyama H, Todo Y, Nomura E, Takeda M et al (2002) Para-aortic lymph node metastasis in relation to serum CA 125 levels and nuclear grade in endometrial carcinoma. Acta Obstet Gynecol Scand 81:458–465\nHsieh CH, ChangChien CC, Lin H, Huang EY, Huang CC, Lan KC et al (2002) Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol 86:28–33\nTodo Y, Sakuragi N, Nishida R, Yamada T, Ebina Y, Yamamoto R et al (2003) Combined use of magnetic resonance imaging, CA 125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma. Am J Obstet Gynecol 188:1265–1272\nJhang H, Chuang L, Visintainer P, Ramaswamy G (2003) CA 125 levels in the preoperative assessment of advanced-stage uterine cancer. Am J Obstet Gynecol 188(5):1195–1197\nSantala M, Talvensaari-Mattila A, Kauppila A (2003) Peritoneal cytology and preoperative serum CA 125 level are important prognostic indicators of overall survival in advanced endometrial cancer. Anticancer Res 23(3C):3097–3103\nPowell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH (2005) Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med 50(8):585–590\nChung HH, Kim JW, Park NH, Song YS, Kang SB, Lee HP (2006) Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand 85:1501–1505\nTodo Y, Okamoto K, Hayashi M, Minobe S, Nomura E, Hareyama H, Takeda M, Ebina Y, Watari H, Sakuragi N (2007) A validation study of a scoring system to estimate the risk of lymph node metastasis for patients with endometrial cancer for tailoring the indication of lymphadenectomy. Gynecol Oncol 104(3):623–628\nHan SS, Lee SH, Kim DH, Kim JW, Park NH, Kang SB et al (2010) Evaluation of preoperative criteria used to predict lymph node metastasis in endometrial cancer. Acta Obstet Gynecol Scand 89:168–174\nKim HS, Park CY, Lee JM, Lee JK, Cho CH, Kim SM et al (2010) Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: a multi-center study. Gynecol Oncol 118:283–288\nLee JY, Jung DC, Park SH, Lim MC, Seo SS, Park SY et al (2010) Preoperative prediction model of lymph node metastasis in endometrial cancer. Int J Gynecol Cancer 20:1350–1355\nSebastianelli A, Renaud MC, Grégoire J, Roy M, Plante M (2010) Preoperative CA 125 tumour marker in endometrial cancer: correlation with advanced stage disease. J Obstet Gynaecol Can 32(9):856–860\nYoon JH, Yoo SC, Kim WY, Chang SJ, Chang KH, Ryu HS (2010) Para-aortic lymphadenectomy in the management of preoperative grade 1 endometrial cancer confined to the uterine corpus. Ann Surg Oncol 17:3234–3240\nChen YL, Huang CY, Chien TY, Huang SH, Wu CJ, Ho CM (2011) Value of pre-operative serum CA125 level for prediction of prognosis in patients with endometrial cancer. Aust N Z J Obstet Gynaecol 51:397–402\nGoksedef BP, Gorgen H, Baran SY, Api M, Cetin A (2011) Preoperative serum CA 125 level as a predictor for metastasis and survival in endometrioid endometrial cancer. J Obstet Gynaecol Can 33(8):844–850\nGupta D, Gunter MJ, Yang K, Lee S, Zuckerwise L, Chen LM, Goldberg GL, Huang GS (2011) Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma. Int J Gynecol Cancer 21(3):529–534\nRoelofsen T, Mingels M, Hendriks JC, Samlal RA, Snijders MP, Aalders AL, Bulten J, van Ham MA, Massuger LF (2012) Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients. Int J Biol Markers 27(3):e263–e271\nKang S, Kang WD, Chung HH, Jeong DH, Seo SS, Lee JM et al (2012) Preoperative identification of a low-risk group for lymph node metastasis in endometrial cancer: a Korean Gynecologic Oncology Group study. J Clin Oncol 30:1329–1334\nNicklin J, Janda M, Gebski V, Jobling T, Land R, Manolitsas T, McCartney A, Nascimento M, Perrin L, Baker JF, Obermair A, LACE Trial Investigators (2012) The utility of serum CA-125 in predicting extra-uterine disease in apparent early-stage endometrial cancer. Int J Cancer 131(4):885–890\nYildiz A, Yetimalar H, Kasap B, Aydin C, Tatar S, Soylu F, Yildiz FS (2012) Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 164(2):191–195\nAntonsen SL, Høgdall E, Christensen IJ, Lydolph M, Tabor A, Loft Jakobsen A, Fagö-Olsen CL, Andersen ES, Jochumsen K, Høgdall C (2013) HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand 92(11):1313–1322\nSaarelainen SK, Peltonen N, Lehtimäki T, Perheentupa A, Vuento MH, Mäenpää JU (2013) Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma. Am J Obstet Gynecol 209(2):142.e1–142.e6\nChao A, Tang YH, Lai CH, Chang CJ, Chang SC, Wu TI, Hsueh S, Wang CJ, Chou HH, Chang TC (2013) Potential of an age-stratified CA125 cut-off value to improve the prognostic classification of patients with endometrial cancer. Gynecol Oncol 129(3):500–504\nHareyama H, Sakuragi N, Makinoda S, Fujimoto S (1996) Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma. J Clin Pathol 49(12):967–970\nNeubauer NL, Lurain JR. (2011) The role of lymphadenectomy in surgical staging of endometrial cancer. Int J Surg Oncol 2011:814649\nConflict of interest\nAll the authors declare that they have no conflict of interest.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nMyriokefalitaki, E., Vorgias, G., Vlahos, G. et al. Prognostic value of preoperative Ca125 and Tag72 serum levels and their correlation to disease relapse and survival in endometrial cancer. Arch Gynecol Obstet 292, 647–654 (2015). https://doi.org/10.1007/s00404-015-3675-4\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-015-3675-4","source_license":"public-domain-us","license_restricted":false}